Literature DB >> 19098868

How I manage H. pylori-negative, NSAID/aspirin-negative peptic ulcers.

Kenneth E L McColl1.   

Abstract

The first and most important action on encountering a patient with unexplained gastric or duodenal ulceration is to double check that they are truly H. pylori negative and also not taking any ulcerogenic medicines. Once the patient is confirmed to be H. pylori negative and NSAID negative, ensure that biopsies of the ulcer-whether gastric or duodenal-and of the surrounding gastric and duodenal mucosa are obtained to exclude underlying malignancy/lymphoma, Crohn's disease, and unusual infectious agents. If the etiology of the ulceration remains unexplained, an underlying gastrinoma should be considered and excluded. Patients with idiopathic ulcers should be maintained on proton pump inhibitor therapy, and higher doses may be required to control acid secretion and prevent ulcer relapse in these H. pylori-uninfected subjects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19098868     DOI: 10.1038/ajg.2008.11

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  11 in total

1.  Helicobacter pylori negative, non-steroidal anti-inflammatory drug-negative peptic ulcers in India.

Authors:  Mahesh Kumar Goenka; Shounak Majumder; Pradeepta Kumar Sethy; Madhurima Chakraborty
Journal:  Indian J Gastroenterol       Date:  2011-03-22

2.  A case of bleeding duodenal ulcer with pemphigus vulgaris during steroid therapy.

Authors:  Kojiro Niho; Akio Nakasya; Ayako Ijichi; Jun Tsujita; Kazuhito Gotoh; Hirotsugu Shinozaki; Masahiro Matsumoto
Journal:  Clin J Gastroenterol       Date:  2014-03-28

3.  Membrane-bound mucins and mucin terminal glycans expression in idiopathic or Helicobacter pylori, NSAID associated peptic ulcers.

Authors:  Yaron Niv; Doron Boltin; Marisa Halpern; Miriam Cohen; Zohar Levi; Alex Vilkin; Sara Morgenstern; Vahig Manugian; Erica St Lawrence; Pascal Gagneux; Sukhwinder Kaur; Poonam Sharma; Surinder K Batra; Samuel B Ho
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

Review 4.  Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding.

Authors:  Takeshi Kanno; Yuhong Yuan; Frances Tse; Colin W Howden; Paul Moayyedi; Grigorios I Leontiadis
Journal:  Cochrane Database Syst Rev       Date:  2022-01-07

5.  Gastric mucin expression in Helicobacter pylori-related, nonsteroidal anti-inflammatory drug-related and idiopathic ulcers.

Authors:  Doron Boltin; Marisa Halpern; Zohar Levi; Alex Vilkin; Sara Morgenstern; Samuel B Ho; Yaron Niv
Journal:  World J Gastroenterol       Date:  2012-09-07       Impact factor: 5.742

6.  Membrane-bound mucins and mucin terminal glycans expression in idiopathic or Helicobacter pylori, NSAID associated peptic ulcers.

Authors:  Yaron Niv; Doron Boltin; Marisa Halpern; Miriam Cohen; Zohar Levi; Alex Vilkin; Sara Morgenstern; Vahig Manugian; Erica St Lawrence; Pascal Gagneux; Surinder K Batra; Samuel B Ho
Journal:  Dig Dis Sci       Date:  2012-05-11       Impact factor: 3.199

7.  Association between early Helicobacter pylori eradication and a lower risk of recurrent complicated peptic ulcers in end-stage renal disease patients.

Authors:  Shen-Shong Chang; Hsiao-Yun Hu
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

8.  High Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up.

Authors:  Hyuk Yoon; Sang Gyun Kim; Hyun Chae Jung; In Sung Song
Journal:  Gut Liver       Date:  2013-03-14       Impact factor: 4.519

9.  Helicobacter pylori Eradication within 120 Days Is Associated with Decreased Complicated Recurrent Peptic Ulcers in Peptic Ulcer Bleeding Patients.

Authors:  Shen Shong Chang; Hsiao-Yun Hu
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 10.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.